Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Rare Inherited Enzyme Disorder Yields Insight into Fibrosis

By LabMedica International staff writers
Posted on 31 Jul 2019
Mammalian tissues and organs preserve their structural and functional homeostasis by means of their supportive connective tissue, a three-dimensional network of cells and extracellular matrix (ECM) with different topological characteristics depending on the organ/tissue in which it is embedded.

An association has been discovered between a deficiency in the enzyme neuraminidase 1 (NEU1) and the build-up of connective tissue (fibrosis) in organs such as the muscle, kidney, liver, heart and lungs. More...
Fibrosis includes life-threatening conditions such as idiopathic pulmonary fibrosis.

An international team of scientists working with the St. Jude Children’s Research Hospital (Memphis, TN, USA) addressed the potential involvement of NEU1 in human fibrosis, they first determined by Masson’s trichrome staining that the fibrotic disease seen in the muscle was a general phenotype of the Neu1−/− connective tissue in different organs. They checked tissue from 89 adults with idiopathic pulmonary fibrosis (IPF) and found NEU1 production was significantly down-regulated as compared to adults without the diagnosis.

Initially the team used a mouse model before confirming their results in human cells. Human lung fibroblasts from control individuals and patients with IPF were obtained and cultured. Fluorescence-activated cell sorting analyses of skeletal muscle connective tissue cells were performed using markers specific on an LSRFortessa flow cytometer instrument. Proliferation assays were performed and every 24 hours for 1 to 4 days and the optical density was read at 490 nm (OD490) with a FLUOstar Omega plate reader. Other methods used in the study included real-time quantitative polymerase chain reaction, immunohistochemistry, exosome isolation, sucrose gradient, proteomics, and size distribution.

The team found that mouse fibroblasts lacking NEU 1 release excessive numbers of molecules that degrade the extracellular matrix, as well as exosomes. The exosomes are loaded with factors that promote fibrosis, including the growth factor TGF-β and the signaling molecule WNT. Normal mouse and human fibroblasts cells were activated to proliferate and migrate when exposed to exosomes containing TGF-β, WNT and related molecules released by NEU1-deficient fibroblasts. The investigators checked an RNA sequencing database of 89 idiopathic pulmonary fibrosis patients and found NEU1 was among the most down-regulated of 66 genes included in the database.

Alessandra d'Azzo, PhD, the senior author of study said, “This is the first time NEU1 has been associated with fibrotic conditions. NEU1 is an important enzyme that breaks down sugar-containing molecules in many cells of the body, but it has not really been on the radar for adult health problems.” The authors concluded that their findings reveal an unexpected exosome-mediated signaling pathway downstream of NEU1 deficiency that propagates a fibrotic disease and could be implicated in idiopathic forms of fibrosis in humans. The study was published on July 17, 2019, in the journal Science Advances.

Related Links:
St. Jude Children’s Research Hospital


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.